about
Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trialFour year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trialThe Interpretive Variability of Cervical Biopsies and Its Relationship to HPV Status.Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer.Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.Variation in HLA class I antigen-processing genes and susceptibility to human papillomavirus type 16-associated cervical cancer.A population-based evaluation of cervical screening in the United States: 2008-2011.No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study.Cervical excisional treatment of young women: a population-based studyThe influence of type-specific human papillomavirus infections on the detection of cervical precancer and cancer: A population-based study of opportunistic cervical screening in the United States.A comparison of cervical histopathology variability using whole slide digitized images versus glass slides: experience with a statewide registryEfficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials.A study of Amplicor human papillomavirus DNA detection in the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study.Impact of improved classification on the association of human papillomavirus with cervical precancer.Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.Human papillomavirus genotypes in cervical intraepithelial neoplasia grade 3Cervical histopathology variability among laboratories: a population-based statewide investigationComparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesionsBeta-test Results for an HPV Information Web site: GoHealthyGirls.org - Increasing HPV Vaccine Uptake in the United StatesHierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage studyPriming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a virus-like particle vaccineProphylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial.Results of the first World Health Organization international collaborative study of detection of human papillomavirus DNA.Concurrence of multiple human papillomavirus infections in a large US population-based cohort.Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial.Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer.CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progressionAge-specific occurrence of HPV16- and HPV18-related cervical cancer.Post hoc analysis of the PATRICIA randomized trial of the efficacy of human papillomavirus type 16 (HPV-16)/HPV-18 AS04-adjuvanted vaccine against incident and persistent infection with nonvaccine oncogenic HPV types using an alternative multiplex tNatural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study.Evaluation of a new DNA test for detection of carcinogenic human papillomavirus.Detection of precancerous cervical lesions is differential by human papillomavirus type.Efficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.The clinical meaning of a cervical intraepithelial neoplasia grade 1 biopsy.Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methodsNoninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines.Investigating stakeholder attitudes and opinions on school-based human papillomavirus vaccination programsUsability Testing of an HPV Information Website for Parents and Adolescents.
P50
Q28236008-BB8FB879-F9E3-402C-80CA-E196F3D227E7Q28750269-BA70738E-DD58-41F5-9AE0-7097E948E000Q30300922-7FB2B233-546D-4D31-9E07-F9D69E11B4BEQ30301333-83540A69-683F-4652-A47B-0B207C34A931Q30354591-F24CD582-6010-4FEB-8397-40D69E15D975Q30367574-50AA8281-A0E8-45F3-ACC5-E51A32AC7C50Q30405438-61CABBA3-C150-4F34-882B-C3CE8B41284AQ30407482-264058C4-03C2-47D0-838F-2B429F0D425AQ30407712-8788C349-750B-4CAD-B770-D4846A9FCDFDQ30409120-17ED5B81-ED04-45BF-8BCA-251C19515B71Q30409771-E5832633-CD86-4E29-80C9-D462C34E1E45Q30970916-2EA7D8DD-AD78-4A4D-8AE5-CF619E7F364CQ33580897-1E3DA170-733E-4919-B051-5513895D5667Q33883581-7383FA37-A87D-47B5-A6D1-029F33A33C0BQ33953881-E188B533-6287-4F9C-9547-3CF26EDD8B83Q33984185-8C8D0B8A-E2FA-45F3-8417-93B1B91E3244Q34017556-2FBA0647-7C76-4740-A983-49BE83ED29FFQ34055574-FEB2EA2E-35B2-4A05-BA06-9B58C04EC600Q34155545-B1AFB123-F124-4E2D-A436-F51C3545F973Q34268415-20AAAA51-EEB1-4408-A0BE-9AA0B237ED70Q34343006-6B68CEBB-A445-4ACC-A155-9F8A679114BDQ34415030-9DC6C973-D762-491E-84F5-316903AE3814Q34430779-4BF96B5A-FD6E-480C-912E-9DFB25B6C97BQ34553582-28C2FB64-917D-448D-8EB2-9E5F68098157Q34580726-993CFC6D-AC96-43B0-922A-2D36D34BA786Q34610151-CAE7CD98-ECA5-41B0-A13D-DEEE206A6F45Q34627305-71B559E3-80FC-488D-94DA-18B7AE47C7D5Q34680748-0E7AB505-1642-498D-8B7C-C3A0B7203263Q34996306-FB61E546-17CC-48E6-8F21-0C60D4E9B829Q35013844-0B03DE74-AAB4-448B-ACAC-27DCA9F32F8FQ35021139-93E9DF57-D4D4-46D8-8B96-6BEFCAD8C46BQ35048280-85171532-4C62-470E-A7E2-78F33BEAD058Q35139772-A63B456E-B436-4BF9-BA18-FC0E6740C1E3Q35163630-C5580A3A-F1CA-4B14-985E-81865A439C9EQ35221177-5ED4F305-C5D1-40FE-ADA9-1243622D7850Q35588255-F6DFDBB5-E4E6-4D67-B688-952C20804A33Q35852900-0FD3E2F5-D993-466F-95CA-D1F8C5E17CD0Q35946997-9E8B9229-9912-444F-8C60-EE79A6DCA01EQ36077071-64A1AE54-AD27-4F68-9C9B-527076386A02Q36303125-E07A7E6D-47C0-492F-BE72-36975C826D0D
P50
name
Cosette M Wheeler
@en
type
label
Cosette M Wheeler
@en
prefLabel
Cosette M Wheeler
@en